See All Slides - tctmd.com

Slides

Presentation TCT 2012

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

What Will We Learn from the EXCEL Trial that We Do Not Already Know?

Presenter: Gregg Stone

October 23, 2012

Presentation TCT 2012

TCT-12. Long-term Follow-up of Catheter-based Renal Denervation for Resistant Hypertension Confirms Durable Blood Pressure Reduction

Presenter: Markus Schlaich

October 23, 2012

Presentation TCT 2012

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

Design of a Fully Drug-Eluting Bioabsorbable Scaffold with EPC-Capture Technology

Presenter: Robert Cottone

October 23, 2012

Presentation TCT 2012

TCT-58. Effects of Mechanical Thrombectomy and Intracoronary Abciximab on Coronary Flow and Infarct Size During Primary PCI: Analysis from the INFUSE-AMI Trial

Presenter: Jan-Henk Dambrink

October 23, 2012

Presentation TCT 2012

Respicardia

Presenter: Robin Germany

October 23, 2012

Presentation TCT 2012

Orsiro (BIOTRONIK) Program Update

Presenter: Stephan Windecker

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

Presenter: Jeffrey Kuvin

October 23, 2012

Presentation TCT 2012

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Presenter: Pedro Moreno

October 23, 2012

Advertisement

Slides

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

What Will We Learn from the EXCEL Trial that We Do Not Already Know?

TCT-12. Long-term Follow-up of Catheter-based Renal Denervation for Resistant Hypertension Confirms Durable Blood Pressure Reduction

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Design of a Fully Drug-Eluting Bioabsorbable Scaffold with EPC-Capture Technology

TCT-58. Effects of Mechanical Thrombectomy and Intracoronary Abciximab on Coronary Flow and Infarct Size During Primary PCI: Analysis from the INFUSE-AMI Trial

Respicardia

Orsiro (BIOTRONIK) Program Update

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content